Tirilazad
Tirilazad is a drug that has been proposed to treat acute ischaemic stroke. When tested on animal models, tirilazad protects brain tissue, and reduces brain damage. However, the drug fails to treat, and even worsens a stroke when studied on a human being.[1]
Clinical data | |
---|---|
Other names | (8S,10S,13S,14S,16R,17S)-17-[2-[4-(2,6-dipyrrolidin-1-ylpyrimidin-4-yl)piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C38H52N6O2 |
Molar mass | 624.874 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Usage in treatment of stroke
Tirilazad currently has no usage in the clinical treatment of stroke.
References
- Bath PM, Iddenden R, Bath FJ, Orgogozo JM (2001). "Tirilazad for acute ischaemic stroke". The Cochrane Database of Systematic Reviews (4): CD002087. doi:10.1002/14651858.CD002087. PMID 11687138.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.